Are Medical Stocks Lagging Addus HomeCare (ADUS) This Year?

Group 1: Company Performance - Addus HomeCare (ADUS) has shown a year-to-date performance increase of approximately 6%, outperforming the Medical sector, which has gained an average of 0% [4] - The Zacks Consensus Estimate for ADUS' full-year earnings has increased by 4.5% over the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [3] - Addus HomeCare currently holds a Zacks Rank of 1 (Strong Buy), suggesting it is positioned well for potential market outperformance in the near term [3] Group 2: Industry Context - Addus HomeCare is part of the Medical - Outpatient and Home Healthcare industry, which consists of 18 companies and is currently ranked 74 in the Zacks Industry Rank [5] - The Medical - Outpatient and Home Healthcare industry has experienced an average gain of 17.6% year-to-date, indicating that while ADUS is performing well, it is slightly underperforming its industry [5] - In contrast, another Medical stock, Arcutis Biotherapeutics, Inc. (ARQT), has a year-to-date return of 2.3% and belongs to the Medical - Biomedical and Genetics industry, which has declined by 9.8% year-to-date [4][6]